Your cart is empty
Start Shopping$37.00
This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.
Molecular Formula | C₁₅₂H₂₅₂N₄₄O₄₂ |
CAS Number | 863288‑34‑0 |
Molar Mass | 3367.94 g/mol |
Amino Acid Sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 |
PubChem CID | 91976842 |
Primary Research Area |
GHRH Analog Growth Hormone Secretagogue Stimulate Endogenous GH/IGF-1 Muscle Growth Fat Metabolism Cellular Repair Recovery Enhancement Anti-aging Effects Growth Hormone Deficiency Lipodystrophy |
Research Summary | Description |
---|---|
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse |
Summary: This study demonstrated that once-daily administration of CJC-1295 (without DAC) was able to normalize body weight and length in GHRH knockout mice. This effect was accompanied by an increase in total pituitary RNA and GH mRNA, suggesting somatotroph cell proliferation. Citation: Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294. |
What is CJC1295 without DAC? |
Summary: This article highlights that CJC1295 without DAC has a relatively short half-life, typically around 30 minutes to an hour. This contrasts sharply with the DAC-modified version, which can have a half-life of 6 to 8 days due to its binding to albumin. Citation: Bocsci. (n.d.). What is CJC1295 without DAC? |
CJC-1295 for beginners: How it works, benefits, dosage, and stacks |
Summary: This article explains that CJC1295 functions by mimicking the body's natural GHRH, stimulating the pituitary gland to release more GH in a pulsatile manner. This mechanism differs from direct exogenous GH administration, which introduces external hormone. Citation: Swolverine. (n.d.). CJC-1295 for Beginners: How it Works, Benefits, Dosage, and Stacks. |
CJC-1295 No DAC vs. CJC-1295 DAC: Key differences, benefits, and best uses |
Summary: This article details that CJC-1295 No DAC produces a pulsatile release of growth hormone that more closely mimics the body's natural GH secretion patterns, often favored for anti-aging, skin rejuvenation, and recovery applications to maintain receptor sensitivity. Citation: Swolverine. (n.d.). CJC-1295 No DAC vs. CJC-1295 DAC: Key Differences, Benefits, and Best Uses. |
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog |
Summary: This study, which introduced CJC-1295 (the DAC version), noted that the first 29 amino acids of GHRH (sermorelin) were as potent as the full 44-amino acid structure, but had rapid metabolic clearance. This led to the development of analogues like Modified GRF (1-29) to enhance biological activity and reduce rapid metabolic clearance. Citation: Jetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I.,... & Abribat, T. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052-3058. |
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. |
Summary: While this study primarily focuses on CJC-1295 with DAC, it is foundational to understanding the broader family of GHRH analogs, including the principles behind CJC-1295 no DAC. This randomized, placebo-controlled, double-blind study in healthy adults (ages 21-61) demonstrated that subcutaneous administration of CJC-1295 (DAC) led to sustained, dose-dependent increases in mean plasma GH concentrations (2- to 10-fold for 6 days or more) and IGF-I concentrations (1.5- to 3-fold for 9-11 days). The estimated half-life of CJC-1295 (DAC) was 5.8-8.1 days. It was found to be safe and relatively well tolerated. This study implies the potential for GHRH analogs to impact GH and IGF-I levels. Citation: Teichman, S. L., Neale, A., Lawrence, B., Gagnon, R., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536 |
CJC-1295 Peptide therapy: Anti-aging, hormone & functional medicine |
Summary: This source describes CJC-1295 (including the no DAC version, often referred to as ""Modified GRF 1-29"") as a GHRH analog that stimulates the pituitary gland to release more growth hormone, subsequently increasing IGF-1. It highlights that the ""no DAC"" version is often preferred for its short half-life, which allows for a more natural, pulsatile release of GH. Reported benefits include increased muscle mass and strength, decreased body fat, enhanced recovery, deeper sleep, improved cognitive function, and anti-aging effects on skin and hair. It also mentions common combination use with Ipamorelin for synergistic effects. Citation: Re-New Institute. (n.d.). CJC 1295. Retrieved from https://www.re-newinstitute.com/content/cjc-1295 |
Summary: This study demonstrated that once-daily administration of CJC-1295 (without DAC) was able to normalize body weight and length in GHRH knockout mice. This effect was accompanied by an increase in total pituitary RNA and GH mRNA, suggesting somatotroph cell proliferation.
Citation: Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294.
Summary: This article highlights that CJC1295 without DAC has a relatively short half-life, typically around 30 minutes to an hour. This contrasts sharply with the DAC-modified version, which can have a half-life of 6 to 8 days due to its binding to albumin.
Citation: Bocsci. (n.d.). What is CJC1295 without DAC?
Summary: This article explains that CJC1295 functions by mimicking the body's natural GHRH, stimulating the pituitary gland to release more GH in a pulsatile manner. This mechanism differs from direct exogenous GH administration, which introduces external hormone.
Citation: Swolverine. (n.d.). CJC-1295 for Beginners: How it Works, Benefits, Dosage, and Stacks.
Summary: This article details that CJC-1295 No DAC produces a pulsatile release of growth hormone that more closely mimics the body's natural GH secretion patterns, often favored for anti-aging, skin rejuvenation, and recovery applications to maintain receptor sensitivity.
Citation: Swolverine. (n.d.). CJC-1295 No DAC vs. CJC-1295 DAC: Key Differences, Benefits, and Best Uses.
Summary: This study, which introduced CJC-1295 (the DAC version), noted that the first 29 amino acids of GHRH (sermorelin) were as potent as the full 44-amino acid structure, but had rapid metabolic clearance. This led to the development of analogues like Modified GRF (1-29) to enhance biological activity and reduce rapid metabolic clearance.
Citation: Jetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I.,... & Abribat, T. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052-3058.
Summary: While this study primarily focuses on CJC-1295 with DAC, it is foundational to understanding the broader family of GHRH analogs, including the principles behind CJC-1295 no DAC. This randomized, placebo-controlled, double-blind study in healthy adults (ages 21-61) demonstrated that subcutaneous administration of CJC-1295 (DAC) led to sustained, dose-dependent increases in mean plasma GH concentrations (2- to 10-fold for 6 days or more) and IGF-I concentrations (1.5- to 3-fold for 9-11 days). The estimated half-life of CJC-1295 (DAC) was 5.8-8.1 days. It was found to be safe and relatively well tolerated. This study implies the potential for GHRH analogs to impact GH and IGF-I levels.
Citation:
Teichman, S. L., Neale, A., Lawrence, B., Gagnon, R., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
Summary: This source describes CJC-1295 (including the no DAC version, often referred to as ""Modified GRF 1-29"") as a GHRH analog that stimulates the pituitary gland to release more growth hormone, subsequently increasing IGF-1. It highlights that the ""no DAC"" version is often preferred for its short half-life, which allows for a more natural, pulsatile release of GH. Reported benefits include increased muscle mass and strength, decreased body fat, enhanced recovery, deeper sleep, improved cognitive function, and anti-aging effects on skin and hair. It also mentions common combination use with Ipamorelin for synergistic effects.
Citation:
Re-New Institute. (n.d.). CJC 1295. Retrieved from https://www.re-newinstitute.com/content/cjc-1295
Your cart is empty
Start Shopping